Car Bruce
Car Bruce's purchase track record
Car Bruce has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/17/2024 | BHVN | $1.01M | +18.3% | +25.6% | +11.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
Transaction History
| BHVN | ▼ Sell | Tax Withholding | 2,381 | $24K | 1/5/2026 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,750 | $0 | 1/5/2026 | View on chart |
| BHVN | ▲ Buy | Option Exercise | 4,750 | $0 | 1/5/2025 | View on chart |
| BHVN | ▼ Sell | Tax Withholding | 2,331 | $90K | 1/5/2025 | View on chart |
| BHVN | ▲ Buy | Open Market | 30,000 | $1.0M | 6/17/2024 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 2,041 | $59K | 2/22/2022 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 6,874 | $0 | 2/18/2022 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 1,073 | $34K | 2/10/2022 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 3,667 | $0 | 2/10/2022 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 3,437 | $0 | 1/6/2022 | View on chart |
| AGIO | ▼ Sell | Tax Withholding | 1,205 | $39K | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Biohaven signs $100M deal with Ono for IgG degraders
Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.
Biohaven signs $100M deal with Ono for IgG degraders. Biohaven has entered a strategic licensing agreement with Ono Pharma for its IgG degrader technology in Japan and select Asian regions. The deal includes up to $100 million in near-term payments, with $80 million paid upfront. This move expands the company's presence in Asia and supports its lead candidate, BHV-1300, which is currently in Phase 3 trials for Graves' disease.